Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj (BR-JELITE)

Boryung

Status and phase

Completed

Phase 4

Conditions

Japanese Encephalitis

Treatments

Biological: Japanese encephalitis vaccine

Study type

Interventional

Funder types

Industry

Identifiers

NCT02532569

BR-KD-287-CT-401

Details and patient eligibility

About

A multi-center, open, phase 4 clinical trial to assess the long-term immunogenicity and safety of fourth administration of Boryung Cell-Culture Japanese Encephalitis Vaccine inj. and to conduct an exploratory investigation on vaccine interchangeability in Korean children aged 6 years who received primary 3 doses with ENCEVAC® or Japanese Encephalitis Vaccine-GCC® inj.

Full description

This is a follow-up study of KD287-BR-CT-301 (ClinicalTrials.gov identifier: NCT01150942), a phase 3 study to investigate the efficacy and safety of a cell-culture Japanese encephalitis vaccine (ENCEVAC®) compared with that of a mouse brain-derived Japanese encephalitis vaccine (Japanese Encephalitis vaccine-GCC® inj). Subjects participated in KD287-BR-CT-301 study were to receive 3 doses of Japanese encephalitis vaccine (JEV) assigned by randomization from the age of 12 months and those subjects who completed the 3 doses of JEV are the target population in this study. The purpose of this study is to investigate the long-term immunogenicity and safety of the booster (fourth) dose of JEV, which will be given as Boryung Cell-Culture Japanese Encephalitis Vaccine inj, proven to be same with ENCEVAC® but manufactured by a different manufacturer.

Enrollment

94 patients

Sex

All

Ages

6 to 7 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Parent/guardian (legally authorized representative) has given voluntary written consent to the subject's participation after being fully informed of the purpose, methods, risks, and benefits of the study.
Male and female children who have completed the primary 3 doses of JEV in the KD287-BR-CT-301study.
Male and female children reaching at least 6 years of age on the day of booster dosing of JEV.
Male and female children who are identified to be healthy based on physical examination and medical history.

Exclusion criteria

Children who have acute febrile illness with tympanic temperature of ≥38.0 ℃ on the day of booster dosing of JEV.
Children who have moderate or severe acute disease (regardless of fever).
Children who have history of encephalitis, encephalopathy, cerebromeningitis, or convulsion.
Children who have received JEV (including live JEV) other than the investigational products administered in the KD287-BR-CT-301study.
Children who have had fever (≥ 40 °C) or systemic allergy within 48 hours after vaccination.
Children who have shown anaphylactic reaction to the investigational products administered in the KD287-BR-CT-301study or who are likely to be allergic to the ingredients of the investigational product.
Children who have been diagnosed with immunodeficiency such as acquired immune deficiency or who have family history of immunodeficiency.
Children who have received other vaccines within 28 days before booster dosing of JEV (vaccines to be administered according to the national vaccination program.
Children who have received immunosuppressive thera-py within 28 days before booster dosing of JEV.
There is a possibility that immune globulin preparations has not been excreted enough on the day of booster dosing of JEV if children have received such a product.
Children who are currently participating or planning to participate in other clinical stud-ies during the study period.
Other ineligible conditions judged at the discretion of principal investigators or subinvestigators.